title: Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine.
abstract: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable subjective effects such as drug "highs" or euphoria in drug-experienced human volunteers. Moreover they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to conclude that the highly unusual stimulant profile of cocaine and related compounds, eg methylphenidate, is not mediated by monoamine reuptake inhibition alone. We describe the experimental findings which suggest cocaine serves as a negative allosteric modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of transport. This results in a firing-dependent, retro-transport of dopamine into the synaptic cleft. The proposed mechanism of cocaine is, therefore, different from other small molecule negative allostereric modulators of the monoamine reuptake transporters, eg SoRI-6238, which merely reduce the rate of inward transport. Because the physiological role of DAT is to remove dopamine from the synapse and the action of cocaine is the opposite of this, we have postulated that cocaine's effect is analogous to an inverse agonist. If this hypothesis is validated then cocaine is the prototypical compound that exemplifies a new class of monoaminergic drugs; DAT "inverse agonists". This article is part of the Special Issue entitled 'CNS Stimulants'.
authors: RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK. Electronic address: david.heal@renasci.co.uk.
authors: David J
authors: DJ
authors: Heal
authors: RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK.
authors: Jane
authors: J
authors: Gosden
authors: RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK. Electronic address: jean.smith@renasci.co.uk.
authors: Sharon L
authors: SL
authors: Smith
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003042:Cocaine / Q000494:pharmacology*; D015259:Dopamine Agents / Q000494:pharmacology*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D006801:Humans; D008774:Methylphenidate / Q000494:pharmacology
chemical_list: D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D008774:Methylphenidate; D003042:Cocaine
keywords: Cocaine; DAT inverse agonist; Dopamine releasing agent; Dopamine reuptake inhibitor; Dopamine transporter; Inverse agonist; Novel mechanism